Digital Health Raised $7.4 Billion in Six Months. A New Report Says Virtual Addiction Care Still Isn't Solving the Real Problem.

U.S. digital health startups raised $7.4 billion across 244 deals in the first half of 2026, a billion more than the same stretch last year — and mega-deals of $100 million or more soaked up 45% of that money in just 8% of the transactions. Mental health has now been the single most-funded clinical category for seven straight years running, with virtual opioid and substance use platforms — Pelago, Bicycle Health, Boulder Care, Eleanor Health, Ophelia, Workit Health, PursueCare among them — building out scaled telehealth models on the strength of that appetite.

More capital is flowing into fewer, larger companies promising to fix opioid treatment access — and an independent evaluation of the actual products just found most of them don’t.

That evaluation is real, and it’s specific. The Peterson Health Technology Institute assessed sixteen virtual OUD solutions against 43 published studies, including 11 randomized controlled trials, sorting the field into two categories: platforms that mainly offer virtual prescribing of buprenorphine or similar medications, and “digital wraparound” products layering services like peer support and contingency management on top of medication-based care. The clinical verdict was genuinely encouraging on paper — comparable outcomes to in-person treatment, with patients on virtual medication-focused platforms staying in treatment about 13 more days over six months than usual care. That’s not nothing; longer retention in medication treatment is one of the more reliable predictors of who survives the next year.

The access verdict is where the story turns. Despite the investment surge, PHTI found no clear evidence that virtual OUD platforms are actually expanding who gets treated, as opposed to giving people who’d already have found care a more convenient way to get it. Digital wraparound products — the ones layered with peer support and behavioral add-ons, the most heavily marketed differentiator in this category — actually increased net spending for the health plans and employers paying for them, because their price tags outran whatever hospitalization and ER costs they helped avoid.

Put those two findings next to each other and the shape of the problem gets clearer: the market is rewarding scale and slick delivery, not the harder, less fundable work of reaching the roughly 85% of people with a substance use disorder who aren’t in treatment at all — often for reasons no app UI solves, like no broadband, no smartphone data plan, no private space to take a telehealth call, or no insurance that covers any of this in the first place. A platform that’s genuinely as good as in-person care for the patient who can already access a phone, privacy, and coverage is a real clinical win. It’s also, on the evidence so far, a business model optimized to serve the easiest patient to reach rather than the hardest one to find.